TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Phase 2

Completed

Conditions: Relapse-Remitting Multiple Sclerosis

Interventions: Drug: glatiramer acetate 20 mg
Drug: glatiramer acetate 40 mg

First Posted Date: 2005-09-20

Last Posted Date: 2010-01-14

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 90

Registration Number: NCT00202982

Locations: 🇺🇸
The MS Center of Atlanta, Atlanta, Georgia, United States
🇺🇸
Michigan Institute of Neurological Disorders, Farmington Hills, Michigan, United States
🇺🇸
Center for Neurologic Study, La Jolla, California, United States

and more 17 locations

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

Phase 2

Completed

Conditions: Relapse Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate, N-Acetylcysteine

First Posted Date: 2005-09-20

Last Posted Date: 2012-05-14

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 18

Registration Number: NCT00203099

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Phase 4

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer acetate

First Posted Date: 2005-09-20

Last Posted Date: 2020-02-18

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 208

Registration Number: NCT00203021

Locations: 🇺🇸
Teva Investigational Site 009, Los Angeles, California, United States
🇺🇸
Teva Investigational Site 004, Los Angeles, California, United States
🇺🇸
Teva Investigational Site 008, New Haven, Connecticut, United States

and more 8 locations

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Phase 4

Terminated

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate
Drug: Betaseron
Drug: Rebif

First Posted Date: 2005-09-20

Last Posted Date: 2010-10-18

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 91

Registration Number: NCT00202995

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Phase 2

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: glatiramer acetate 20 mg
Drug: glatiramer acetate 20 mg, with mitoxantrone

First Posted Date: 2005-09-20

Last Posted Date: 2011-04-14

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 40

Registration Number: NCT00203073

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

Phase 3

Completed

Conditions: Parkinson's Disease

First Posted Date: 2005-09-20

Last Posted Date: 2011-04-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 55

Registration Number: NCT00203125

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Phase 2

Completed

Conditions: Relapse Remitting Multiple Sclerosis

Interventions: Drug: glatiramer acetate with minocycline
Drug: Glatiramer acetate with placebo

First Posted Date: 2005-09-20

Last Posted Date: 2011-04-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 44

Registration Number: NCT00203112

Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson's Disease

First Posted Date: 2005-09-20

Last Posted Date: 2011-04-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 306

Registration Number: NCT00203138

A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: edratide

First Posted Date: 2005-09-20

Last Posted Date: 2011-04-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 340

Registration Number: NCT00203151

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Completed

Conditions: Parkinson's Disease
Malignant Melanoma

First Posted Date: 2005-09-20

Last Posted Date: 2010-10-18

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 2106

Registration Number: NCT00203008

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy